Farnesoid X Receptor Activation Prevents the Development of Vascular Calcification in ApoE-/- Mice With Chronic Kidney Disease

被引:83
作者
Miyazaki-Anzai, Shinobu
Levi, Moshe
Kratzer, Adelheid
Ting, Tabitha C.
Lewis, Linda B.
Miyazaki, Makoto [1 ,2 ]
机构
[1] Univ Colorado Denver, Div Renal Dis & Hypertens, Dept Med, Denver Vet Affairs Med Ctr, Aurora, CO 80045 USA
[2] Denver Vet Affairs Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Denver, CO USA
关键词
farnesoid X receptor; vascular calcification; chronic kidney disease; FXR-MEDIATED REGULATION; BILE-ACID; NUCLEAR RECEPTOR; CELL CALCIFICATION; GENE-EXPRESSION; METABOLISM; MECHANISMS; ATHEROSCLEROSIS; INFLAMMATION; DISRUPTION;
D O I
10.1161/CIRCRESAHA.109.212969
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Vascular calcification is highly associated with cardiovascular morbidity and mortality, especially in patients with chronic kidney disease. The nuclear receptor farnesoid X receptor (FXR) has been implicated in the control of lipid, carbohydrate and bile acid metabolism in several cell types. Although recent studies have shown that FXR is also expressed in vascular smooth muscle cells, its physiological role in vasculature tissue remains obscure. Objective: Here, we have examined the role of FXR in vascular calcification. Methods and Results: The FXR gene, a bile acid nuclear receptor, was highly induced during osteogenic differentiation of bovine calcifying vascular cells (CVCs) and in the aorta of apolipoprotein (Apo) E-/- mice with chronic kidney disease which are common tissue culture and mouse model, respectively, for aortic calcification. FXR activation by a synthetic FXR agonist, 6 alpha-ethyl chenodeoxycholic acid (INT-747) inhibited phosphate induced-mineralization and triglyceride accumulation in CVCs. FXR dominant negative expression augmented mineralization of CVCs and blocked the anticalcific effect of INT-747 whereas VP16FXR that is a constitutively active form reduced mineralization of CVCs. INT-747 treatment also increased phosphorylated c-Jun N-terminal kinase (JNK). SP600125 (specific JNK inhibitor) significantly induced mineralization of CVCs and alkaline phosphatase expression, suggesting that the anticalcific effect of INT-747 is attributable to JNK activation. We also found that INT-747 ameliorates chronic kidney disease induced-vascular calcification in 5/6 nephrectomized ApoE(-/-) mice without affecting the development of atherosclerosis. Conclusions: These observations provide direct evidence that FXR is a key signaling component in regulation of vascular osteogenic differentiation and, thus representing a promising target for the treatment of vascular calcification. (Circ Res. 2010;106:1807-1817.)
引用
收藏
页码:1807 / U55
页数:25
相关论文
共 46 条
  • [11] Effects of FXR in foam-cell formation and atherosclerosis development
    Guo, Grace L.
    Santamarina-Fojo, Silvia
    Akiyama, Taro E.
    Amar, Marcelo J. A.
    Paigen, Beverly J.
    Brewer, Bryan
    Gonzalez, Frank J.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2006, 1761 (12): : 1401 - 1409
  • [12] Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice
    Hanniman, EA
    Lambert, G
    McCarthy, TC
    Sinal, CJ
    [J]. JOURNAL OF LIPID RESEARCH, 2005, 46 (12) : 2595 - 2604
  • [13] Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice
    Hartman, Helen B.
    Gardell, Stephen J.
    Petucci, Chris J.
    Wang, Shuguang
    Krueger, Julie A.
    Evans, Mark J.
    [J]. JOURNAL OF LIPID RESEARCH, 2009, 50 (06) : 1090 - 1100
  • [14] Endocrine functions of bile acids
    Houten, SM
    Watanabe, M
    Auwerx, J
    [J]. EMBO JOURNAL, 2006, 25 (07) : 1419 - 1425
  • [15] T0901317, an LXR agonist, augments PKA-induced vascular cell calcification
    Hsu, Jeffrey J.
    Lu, Jinxiu
    Huang, Michael S.
    Geng, Yifan
    Sage, Andrew P.
    Bradley, Michelle N.
    Tontonoz, Peter
    Demer, Linda L.
    Tintut, Yin
    [J]. FEBS LETTERS, 2009, 583 (08): : 1344 - 1348
  • [16] Mineralocorticoid receptor activation promotes vascular cell calcification
    Jaffe, Iris Z.
    Tintut, Yin
    Newfell, Brenna G.
    Demer, Linda L.
    Mendelsohn, Michael E.
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (04) : 799 - 805
  • [17] Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy
    Jiang, Tao
    Wang, Xiaoxin X.
    Scherzer, Pnina
    Wilson, Paul
    Tallman, James
    Takahashi, Hideaki
    Li, Jinping
    Iwahashi, Mieko
    Sutherland, Eileen
    Arend, Lois
    Levi, Moshe
    [J]. DIABETES, 2007, 56 (10) : 2485 - 2493
  • [18] Vascular calcification - Pathobiological mechanisms and clinical implications
    Johnson, Rebecca C.
    Leopold, Jane A.
    Loscalzo, Joseph
    [J]. CIRCULATION RESEARCH, 2006, 99 (10) : 1044 - 1059
  • [19] Vascular calcification in chronic kidney disease
    Jono, S
    Shioi, A
    Ikari, Y
    Nishizawa, Y
    [J]. JOURNAL OF BONE AND MINERAL METABOLISM, 2006, 24 (02) : 176 - 181
  • [20] Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats
    Katsumata, K
    Kusano, K
    Hirata, M
    Tsunemi, K
    Nagano, N
    Burke, SK
    Fukushima, N
    [J]. KIDNEY INTERNATIONAL, 2003, 64 (02) : 441 - 450